Results 11 to 20 of about 5,749 (154)

External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy [PDF]

Frontiers in Medicine, 2021
Background and Aim: A prediction model of hepatocellular carcinoma (HCC) risk in patients with chronic liver diseases, based on age, male sex, albumin-bilirubin, and platelets (aMAP), has been previously reported. We validated the aMAP score and compared
Honglian Gui, Yan Huang, Gangde Zhao, Lichang Chen, Wei Cai, Hui Wang, Qing Guo, Qing Xie   +7 more
doaj   +5 more sources

Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify. [PDF]

Br J Cancer, 2022
Abstract Background and aims The aMAP score is a model that predicts risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis. Its performance in a ‘real world’ surveillance setting has not yet been ascertained. Patients and methods We had access
Johnson PJ, Innes H, Hughes DM, Kalyuzhnyy A, Kumada T, Toyoda H.   +5 more
europepmc   +6 more sources

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis [PDF]

Journal of Hepatology, 2020
Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB)
Rong Fan, George Papatheodoridis, Jian Sun, Hamish Innes, Hidenori Toyoda, Qing Xie, Shuyuan Mo, Vana Sypsa, Indra Neil Guha, Takashi Kumada, Junqi Niu, George Dalekos, Satoshi Yasuda, Eleanor Barnes, Jianqi Lian, Vithika Suri, Ramazan Idilman, Stephen T. Barclay, Xiaoguang Dou, Thomas Berg, Peter C. Hayes, John F. Flaherty, Yuanping Zhou, Zhengang Zhang, Maria Buti, Sharon J. Hutchinson, Yabing Guo, Jose Luis Calleja, Lanjia Lin, Longfeng Zhao, Yongpeng Chen, Harry L.A. Janssen, Chaonan Zhu, Lei Shi, Xiaoping Tang, Anuj Gaggar, Lai Wei, Jidong Jia, William L. Irving, Philip J. Johnson, Pietro Lampertico, Jinlin Hou   +41 more
openaire   +9 more sources

Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study [PDF]

Journal of Gastrointestinal Oncology, 2021
Long-term survivals of patients with HBV-related hepatocellular carcinoma are limited by the high incidence of tumor recurrence after radiofrequency ablation (RFA), identification of the risk factors and understanding the patterns of recurrence can help to improve the comprehensive management of patients after RFA.
Yujing, Xin, Xinyuan, Zhang, Yi, Yang, Yi, Chen, Yanan, Wang, Xiang, Zhou, Xiao, Li   +6 more
openaire   +4 more sources

Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study

Journal of Hepatocellular Carcinoma, 2021
Yi Yang, 1,* Yanzhao Zhou, 2, 3,* Xinyuan Zhang, 1,* Yujing Xin, 1 Yi Chen, 1, 4 Qingsheng Fan, 5 Xiao Li, 1 Xi Wei, 6 Qiang Li, 3 Xiang Zhou, 1 Jinxue Zhou 2 1Department of Interventional Therapy, National Cancer Center/National Clinical Research ...
Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J   +10 more
doaj   +4 more sources

Assessing the Predictive Accuracy of the aMAP Risk Score for Hepatocellular Carcinoma (HCC): Diagnostic Test Accuracy and Meta-analysis. [PDF]

J Clin Exp Hepatol
We aimed to perform a meta-analysis with the intention of evaluating the reliability and test accuracy of the aMAP risk score in the identification of HCC.A systematic search was performed in PubMed, Scopus, Cochrane, Embase, and Web of Science databases from inception to September 2023, to identify studies measuring the aMAP score in patients for the ...
Elgenidy A, Abubasheer TM, Odat RM, Abdelrahim MG, Jibril NS, Ramadan AM, Ballut L, Haseeb ME, Ragab A, Ismail AM, Afifi AM, Mohamed BJ, Jalal PK.   +12 more
europepmc   +5 more sources

The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study. [PDF]

J Cancer, 2023
Background: A less effective nomogram for patients with intermediate-stage hepatocellular carcinoma (HCC) to predict overall survival (OS) is available. This study aimed to investigate the role of age-male-albumin-bilirubin-platelet (aMAP) scores in the prognosis of patients with intermediate-stage HCC and develop an aMAP score-based nomogram to ...
Chen Y, Shi Y, Lu L, Wang X, Lin Q, Lin Y, Wang R, Zhu H, Zheng P, Chen X.   +9 more
europepmc   +3 more sources

External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs [PDF]

Journal of Hepatology, 2021
Gamal Shiha, Nabiel Mikhail, Reham Soliman   +2 more
openaire   +4 more sources

Reply to: “External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs” [PDF]

Journal of Hepatology, 2021
Rong Fan, Xueru Yin, Jinlin Hou
openaire   +4 more sources

[Application of aMAP score to assess the risk of hepatocarciongenesis in population of chronic liver disease in primary hospitals]. [PDF]

Zhonghua Gan Zang Bing Za Zhi, 2021
Objective: The aMAP score is a hepatocellular carcinoma (HCC) risk prediction model based on an international cooperative cohort, which can be applied to various liver diseases. The aim of this study is to use the aMAP score to stratify the risk of HCC in patients with chronic liver disease (combined or non-combined metabolic diseases) admitted to ...
Li XH, Hao X, Deng YH, Liu XQ, Liu HY, Zhou FY, Fan R, Guo YB, Hou JL.   +8 more
europepmc   +3 more sources